A mast cell is a granule-rich white blood cell that resides mainly in tissues and responds to environmental, infectious, and physiological signals by releasing biologically active substances. Mast cells are particularly abundant beneath epithelial surfaces and near blood vessels and nerves, placing them at interfaces between the body and its surroundings. Their products include histamine, proteolytic enzymes, lipid mediators, and signaling proteins that can rapidly alter vascular permeability, smooth-muscle activity, and the behavior of other immune cells.
Mast cells belong to the innate immune system, but they also provide an important connection to adaptive immunity. Their high-affinity receptors for immunoglobulin E (IgE) allow antigen-specific antibodies to trigger immediate responses. This mechanism is central to many allergic reactions, including some forms of anaphylaxis. Other mast-cell responses do not require IgE and can be initiated by microbial products, complement fragments, certain drugs, and signals released during tissue injury.
Mast cells are not simply cells that cause allergy. Their development, granule composition, receptor expression, and effects vary with their tissue environment. They participate in selected forms of host defense, communication between nerves and immune cells, and tissue remodeling. Abnormal activation can cause disease without an increase in cell number, whereas clonal proliferation produces a distinct group of disorders collectively called mastocytosis.
Discovery, morphology, and cellular identity
The German physician and scientist Paul Ehrlich described mast cells in the 1870s and discussed them in his 1878 doctoral work on tissue staining. He named them Mastzellen, using a German term associated with feeding or fattening, because their conspicuous cytoplasmic granules suggested unusually well-nourished cells. The name therefore reflects an early interpretation of their appearance, not their modern physiological definition. Their identity as major sources of histamine and as effectors of immediate hypersensitivity emerged through research during the twentieth century.
Mature mast cells are generally round or oval when isolated, although their shape in tissues can be elongated or irregular. They commonly measure roughly 10–20 micrometres across, with considerable variation according to species, tissue, and activation state. A usually round or oval nucleus is surrounded by numerous membrane-bound secretory granules. These granules may obscure the nucleus in routinely stained preparations. Unlike some circulating granulocytes, normal mature mast cells do not characteristically have a segmented nucleus.
A defining microscopic feature is metachromasia: dyes such as toluidine blue can stain the granules a color different from that of the dye solution. This occurs because densely packed, negatively charged granule constituents alter the optical behavior of bound dye molecules. Sulfated proteoglycans, including those carrying heparin chains, contribute to this property. Electron microscopy reveals structurally diverse granules, sometimes with dense cores, scroll-like patterns, or crystalline arrangements. Granule appearance depends partly on species and tissue location and is not, by itself, a complete functional classification.
Mast cells differ from basophils, despite sharing histamine-containing granules and high-affinity IgE receptors. Basophils normally circulate in blood, have a lobulated nucleus, and are relatively short-lived. Mast cells normally complete their maturation in tissues and may persist there for long periods. The two cell types arise through distinct developmental programs rather than representing circulating and tissue stages of the same mature cell. This distinction is important because experimental measurements of basophil activation do not directly measure mast-cell behavior.
Modern identification combines morphology with molecular markers. Most human mast cells strongly express the receptor KIT, also called CD117, and contain the granule protease tryptase. Neither marker should be interpreted without context: KIT occurs on other cell populations, and immature or abnormal mast cells may have unusual staining patterns. Tissue location, granule morphology, receptor expression, and, where relevant, molecular findings together establish cellular identity more reliably than a single marker.
Development and maintenance in tissues
Mast cells belong to the blood-forming system, although mature cells are predominantly tissue residents rather than circulating cells. Their precursors arise through hematopoiesis and reach peripheral tissues while still relatively immature. Local signals then determine survival, maturation, granule composition, and responsiveness. This arrangement contrasts with that of many other white blood cells, which leave the bone marrow with much of their mature phenotype already established.
A central developmental pathway involves stem cell factor and its receptor, the KIT receptor. KIT is a receptor tyrosine kinase encoded by the KIT gene. Binding of stem cell factor promotes receptor dimerization and signaling through pathways that support proliferation, survival, migration, and differentiation. Stromal cells, epithelial cells, and other tissue components can provide stem cell factor in membrane-bound or soluble forms. Its importance is demonstrated by the profound mast-cell deficiencies found in several mouse strains with impaired KIT signaling.
Mast-cell development is also regulated by transcriptional programs. The transcription factors GATA2 and MITF have major roles in establishing or maintaining mast-cell identity, while other regulators influence developmental choices shared with related blood-cell lineages. Cytokines modify these programs rather than acting as interchangeable growth signals. Interleukin-3 is widely used to generate mouse bone-marrow-derived mast cells in culture, but this culture system does not reproduce every feature of mature human tissue mast cells. Human mast-cell cultures generally depend strongly on stem cell factor and often require weeks to develop abundant granules.
Developmental lineage studies, especially in mice, have complicated the older view that all adult mast cells are continuously replaced from adult bone marrow. Embryonic progenitors can seed tissues before birth, and some populations persist through local maintenance. Adult-derived progenitors contribute to other compartments and can become particularly important during inflammation or tissue replacement. The balance between embryonic origin, adult recruitment, and local proliferation differs among tissues. Directly mapping equivalent processes in humans is more difficult, so mouse lineage relationships cannot simply be assigned to human populations.
Once established, mast cells respond continuously to their surroundings. Signals from fibroblasts, epithelium, nerves, and neighboring immune cells can change their receptor expression and mediator content. Some populations are relatively long-lived, while others expand or contract with inflammation. Following activation, a mast cell need not die: it can replenish granules and respond again. Cell abundance therefore reflects several processes—precursor entry, local division, survival, and cell loss—rather than a single rate of production in bone marrow.
Tissue distribution and functional diversity
Mast cells are strategically positioned in tissues exposed to the external environment, including skin, respiratory mucosa, and the gastrointestinal tract. They also occur in connective tissues around blood vessels, glands, and peripheral nerves. Their distribution makes them sensitive both to material entering across epithelial barriers and to internal changes such as tissue damage or altered neural activity. They are normally uncommon as mature cells in peripheral blood, and their density is highly variable between anatomical sites.
Human mast cells have traditionally been divided according to their protease content. The category contains tryptase but little or no detectable chymase, whereas cells contain both tryptase and chymase and commonly express additional proteases, including carboxypeptidase A3. Tryptase-dominant cells are prominent in several mucosal locations, while cells containing both major proteases are abundant in skin and other connective tissues. These patterns are useful descriptive tendencies, not rigid boundaries. Disease, local cytokines, and maturation state can modify protease expression.
The familiar distinction between connective-tissue and mucosal mast cells comes largely from rodent studies. In mice, these populations differ in granule proteoglycans, protease repertoires, growth requirements, and responses to particular stimuli. Connective-tissue mast cells commonly contain heparin-rich granules, whereas mucosal populations have different glycosaminoglycan profiles. Human protease-defined categories overlap only partly with these rodent categories. Treating them as exact equivalents can lead to incorrect conclusions about drug responses or immune function.
Variation extends well beyond granule enzymes. Human skin mast cells often express substantial amounts of MRGPRX2, a receptor responsive to several positively charged peptides and drugs. Its expression and functional importance differ in other tissues. Mast cells also vary in their expression of receptors for complement fragments, cytokines, neuropeptides, and microbial signals. Consequently, two mast cells carrying similar amounts of histamine may react very differently to the same stimulus.
Studies using RNA sequencing, including single-cell approaches, have revealed tissue-associated expression states that are more complex than a two-category classification. Some differences reflect stable developmental or anatomical specialization; others reflect transient activation or adaptation to disease. Technical handling also matters because tissue digestion and cell isolation can change expression or preferentially recover certain cells. A useful description therefore specifies the species, anatomical site, isolation method, and measured features. “Mast cell” identifies a recognizable cell lineage, but it does not imply that every member has the same receptors, granule contents, or biological effects.
Recognition of stimuli and activation pathways
The best-characterized mast-cell activation pathway begins with IgE bound to the high-affinity receptor FcεRI on the cell membrane. IgE is produced by differentiated B cells and can remain receptor-bound even when no reaction is occurring. An appropriate multivalent antigen brings neighboring receptor-bound IgE molecules together, aggregating FcεRI complexes. Receptor occupancy alone is not equivalent to activation: the geometry and extent of receptor aggregation, together with the cell’s signaling state, influence the response.
FcεRI signaling involves phosphorylation of receptor-associated activation motifs and recruitment of enzymes including the tyrosine kinase SYK. Downstream signaling activates phospholipase C, generates intracellular messengers, releases calcium from intracellular stores, and promotes calcium entry through membrane channels. Changes in calcium concentration cooperate with protein kinase pathways and the cytoskeleton to support granule transport and fusion with the plasma membrane. Other branches activate transcription factors that induce cytokine production. Immediate secretion and later gene expression are therefore related but separable outputs.
Rapid release of granule contents is called degranulation. It can involve fusion of individual granules with the cell surface or fusion among granules before their contents are discharged. Mast cells can also release selected products without undergoing extensive, coordinated granule emptying. A stimulus that strongly induces cytokine synthesis may cause little histamine release, while another may produce rapid secretion with a different pattern of newly synthesized mediators. Describing a cell as “activated” is consequently incomplete unless the measured response is specified.
Several pathways operate independently of IgE. Components of the complement system, notably C3a and C5a, can activate responsive mast-cell populations through their respective receptors. Toll-like receptors and other recognition systems detect microbial molecules and may induce inflammatory gene expression without the classic pattern of immediate degranulation. Extracellular ATP, tissue-derived cytokines, and neuropeptides provide additional signals. Interleukin-33, released or exposed in association with tissue stress, acts through the ST2 receptor and can amplify mast-cell responses in suitable contexts.
MRGPRX2, a G protein-coupled receptor, explains some rapid reactions to cationic drugs and peptides without prior IgE sensitization. Its mouse counterpart, MrgprB2, has related but nonidentical ligand responsiveness. Activation thresholds are also restrained by inhibitory receptors and intracellular phosphatases. The resulting behavior reflects an integration of positive and negative signals, not an automatic response to every encountered ligand. This signaling diversity helps explain why a substance can activate mast cells in one tissue, species, or experimental preparation but have little effect in another.
Stored mediators and newly synthesized products
Mast-cell mediators differ in where they are stored, how quickly they appear, and how long their effects persist. Preformed granule constituents can be released within seconds to minutes of a strong stimulus. Lipid mediators are synthesized rapidly from membrane-derived precursors, while many cytokines and chemokines require transcription, translation, and secretion over a longer interval. These phases overlap, and some cytokines can also be present in preformed pools. The overall response is therefore a changing mixture rather than the action of one substance.
Histamine is the best-known granule mediator. Through different histamine receptors, it can increase vascular permeability, contribute to vasodilation, stimulate sensory nerves, and affect smooth muscle and glandular secretion. Its effects depend on receptor distribution: histamine signaling is not identical in a skin vessel, an airway, and a sensory nerve. Because histamine is rapidly metabolized and is also produced by other cells, its measurement has limitations as a specific indicator of mast-cell activity.
Granule proteases include tryptases, chymase, and carboxypeptidase A3. These enzymes can cleave extracellular proteins, process signaling molecules, and alter components of the extracellular matrix. Their consequences depend on substrate availability, local inhibitors, and whether the enzyme remains associated with granule material. Proteoglycans help package and stabilize these positively charged proteins within granules. Although heparin has powerful anticoagulant properties when used pharmacologically, the presence of heparin in mast-cell granules does not establish a general role for mast cells as systemic anticoagulant cells.
Newly synthesized lipid products include prostaglandin D₂ and cysteinyl leukotrienes, particularly leukotriene C₄ and its extracellular metabolites. These arise from arachidonic acid through distinct enzymatic pathways. Prostaglandin D₂ can influence vascular responses and recruit receptor-bearing inflammatory cells. Cysteinyl leukotrienes can promote bronchial smooth-muscle contraction, mucus secretion, and vascular leakage. Their biological actions may continue after the initial pulse of histamine has declined.
Mast cells also produce a context-dependent range of cytokines and chemokines, including tumor necrosis factor and mediators that attract or regulate other leukocytes. Some products promote inflammation, whereas others can limit particular immune responses. Mouse mast cells commonly contain substantial serotonin, but serotonin is not a comparably dominant mediator in typical human mast cells. Such species differences are important when interpreting animal experiments. No single list of mediators captures every mast-cell population, and detection of a mediator in a cultured cell does not establish that it is released at biologically important concentrations in intact human tissue.
Host defense, tissue repair, and neuroimmune communication
Mast cells can respond early to infection because of their location beneath epithelial barriers and their ability to release mediators rapidly. Increased blood flow, vascular permeability, and chemokine production can facilitate recruitment of neutrophils and other effector cells. In selected experimental infections, mast-cell products improve local pathogen control or influence the development of subsequent immune responses. These effects are not universally protective: excessive vascular leakage or inflammatory amplification can also contribute to tissue damage.
One well-established experimental area concerns immunity to parasitic worms. In several mouse models, intestinal mast-cell expansion and activation contribute to changes in epithelial permeability, mucus-associated responses, and worm expulsion. Interactions with type 2 immune pathways are important, including signals associated with interleukins 4, 9, and 13. The contribution varies with the parasite and infection stage. Mast cells are therefore participants in some anti-helminth responses, not a universal or independently sufficient defense against all parasites.
Mast-cell proteases can modify toxins and endogenous peptides. Experimental studies have shown that particular proteases can degrade selected venom components or toxic peptides and improve survival in defined animal models. The same capacity to cleave proteins can be harmful in another setting if it disrupts a protective barrier or destroys regulatory molecules. Protective effects observed with one venom, dose, or route of exposure cannot be generalized to all envenomation. Both the biochemical substrate and the timing of enzyme release matter.
In injured tissues, mast cells interact with fibroblasts, vascular cells, and matrix proteins. Their mediators can influence vessel formation, matrix degradation, fibroblast activity, and collagen deposition. These processes connect mast cells to wound repair and fibrosis, but experimental findings vary substantially by organ and disease model. An increased number of mast cells in fibrotic tissue does not, by itself, establish that they initiated or sustain the fibrosis. They may be drivers, modifiers, or cells recruited by the same signals affecting other tissue populations.
Mast cells also participate in communication with the nervous system. They frequently lie near sensory nerve endings, which can respond to histamine, proteases, and lipid mediators. Conversely, neuropeptides can alter mast-cell behavior, creating local feedback circuits. These interactions contribute to mechanisms of itch and can influence pain and neurogenic inflammation. Mast cells can also affect dendritic cells, T cells, and other immune populations through soluble mediators and local contact-dependent processes. Their role is best understood as context-sensitive coordination at tissue interfaces rather than as a single fixed inflammatory function.
IgE-mediated allergy and immediate hypersensitivity
In IgE-mediated allergy, an immune response develops against a substance that is otherwise often harmless at ordinary exposure levels. During sensitization, allergen-specific B cells undergo antibody class switching and produce IgE under the influence of appropriate T-cell signals. IgE then binds FcεRI on mast cells. Sensitization may occur without obvious symptoms, and the presence of allergen-specific IgE does not by itself establish that exposure will produce clinical disease.
On subsequent exposure, an allergen capable of cross-linking the relevant IgE molecules can trigger mast-cell secretion. Local consequences depend heavily on the exposure site. In skin, mediator release can produce an itchy wheal and surrounding redness. In the nose, it contributes to sneezing, secretion, and congestion. In the lower airways, bronchoconstriction, mucus production, and inflammatory recruitment can impair airflow. Mast cells contribute to several forms of asthma, but asthma is heterogeneous and cannot be reduced to a single cell type or an exclusively IgE-dependent mechanism.
The early phase of an allergic reaction develops within minutes and reflects preformed and rapidly synthesized mediators. A later phase can arise over subsequent hours as chemokines, cytokines, and vascular changes recruit additional cells, including eosinophils and T cells. Persistent exposure can alter tissue structure and responsiveness. Mast cells can both initiate and amplify these events, while epithelial cells, lymphocytes, and other innate cells contribute additional pathways. Chronic allergic inflammation is therefore more complex than repeated bursts of histamine alone.
Anaphylaxis is a rapid systemic hypersensitivity reaction that can involve several organ systems, including the circulation and respiratory tract. Mast-cell and basophil mediators can produce widespread vascular leakage, loss of vascular tone, bronchoconstriction, and other abnormalities. Many cases are IgE-mediated, but clinically similar reactions can arise through other mechanisms. The severity of a reaction is influenced by multiple factors, including the trigger, exposure route, underlying disorders, and physiological cofactors; it cannot be inferred solely from the amount of circulating allergen-specific IgE.
Not all common mast-cell-associated skin disease reflects an external allergen. Chronic spontaneous urticaria, for example, involves recurrent wheals, angioedema, or both, and in some patients is associated with autoimmune mechanisms affecting the IgE–FcεRI pathway. Therapeutic approaches illustrate the distinct levels of this biology: histamine-receptor antagonists block selected mediator effects, while anti-IgE antibodies alter IgE availability and can reduce FcεRI expression. These mechanisms do not imply that every response to such treatment identifies a single underlying cause, nor that all mast-cell mediators are blocked equally.
Mastocytosis and mast-cell activation disorders
Mastocytosis is a group of disorders characterized by clonal accumulation of mast cells. Cutaneous forms primarily involve the skin, whereas systemic forms involve extracutaneous tissues, commonly including bone marrow. Clinical effects can result from mediator release, tissue infiltration, or both. Childhood cutaneous disease and adult systemic disease have different typical patterns, and the presence of skin lesions alone does not determine the full extent of involvement.
An activating KIT mutation, especially the D816V substitution, is found in most adults with systemic mastocytosis when sufficiently sensitive methods are used. The mutation alters KIT signaling and supports abnormal cell survival or proliferation. Additional genetic changes can occur, particularly in advanced disease or associated blood-cell neoplasms. Classification distinguishes relatively indolent forms from advanced forms with organ damage, and also recognizes mast cell leukemia and disease associated with another hematologic neoplasm. Mutation detection is informative but must be interpreted alongside tissue morphology and other findings.
Diagnosis of systemic mastocytosis uses combinations of tissue and laboratory criteria rather than an isolated symptom or blood result. Relevant findings include dense aggregates of mast cells, atypical cellular morphology, activating KIT mutations, and abnormal expression of markers such as CD25, CD2, or CD30. Persistently elevated basal serum tryptase is another criterion with important qualifications. Diagnostic frameworks published by major classification groups differ in some details, including the handling of associated neoplasms and inherited causes of elevated tryptase.
Mast-cell activation syndrome describes recurrent systemic episodes attributed to inappropriate mediator release when consensus clinical, biochemical, and response criteria are fulfilled. A central biochemical criterion is an event-related increase in serum tryptase above the individual’s baseline. The commonly used threshold is
This formula accommodates both low and high baseline values. Sampling time matters because tryptase rises and subsequently falls after many systemic activation events. A normal baseline does not exclude anaphylaxis, and a persistently high baseline does not prove ongoing activation.
Activation disorders may be associated with a clonal mast-cell population, arise secondarily to an identifiable trigger such as allergy, or remain unexplained after evaluation. They are not synonymous with mastocytosis. Hereditary alpha-tryptasemia, caused by increased copy number of alpha-tryptase-encoding sequences in TPSAB1, is another reason for elevated basal tryptase; it does not itself establish mastocytosis or mast-cell activation syndrome. Symptoms attributed to mediator release overlap with many other conditions, making objective evidence and defined diagnostic criteria essential to distinguishing these entities.
Experimental methods and limits of interpretation
Mast cells are studied through tissue histology, cell culture, mediator measurements, molecular profiling, and animal models. Immunohistochemistry for tryptase, KIT, and additional markers establishes their distribution within tissue and can identify abnormal patterns. Flow cytometry provides multiparameter characterization of isolated cells, including aberrant surface markers in clonal disease. Each method sacrifices some information: tissue staining preserves spatial relationships but measures limited features, whereas cell isolation permits detailed analysis but disrupts the original environment.
Functional experiments commonly measure histamine or beta-hexosaminidase release as indicators of granule secretion. Calcium imaging detects early signaling, while immunoassays and lipid analysis quantify selected secreted products. These readouts are not interchangeable. A cell may release cytokines without substantial beta-hexosaminidase release, and reduced secretion can reflect cell injury rather than specific inhibition of an activation pathway. Meaningful comparisons therefore require attention to cell viability, stimulus strength, incubation time, and the particular mediator being measured.
Cultured cells provide experimental control but introduce developmental biases. Mouse bone-marrow-derived mast cells are accessible and reproducible, yet they do not fully represent every mature tissue population. Human cells can be generated from blood or other progenitors, while primary tissue mast cells retain some site-specific features but are harder to obtain and maintain. Immortalized mast-cell lines may carry signaling mutations or lack receptors present in normal cells. Findings from a cell line therefore require validation before being assigned to normal human mast-cell physiology.
Animal studies have historically relied heavily on mice with defective KIT signaling. These animals can have abnormalities beyond mast-cell deficiency, including changes in other blood-cell populations and tissue physiology. Reconstitution with cultured mast cells helps address some questions but may not restore natural anatomical distribution or developmental history. More selective genetic depletion systems avoid some KIT-related confounding, yet their specificity depends on the promoter, tissue, and timing of the intervention. Agreement among several complementary models is more persuasive than a result from one deficient strain.
Single-cell expression profiling, spatial methods, and proteomic analysis increasingly connect cellular state with anatomical context. Important unresolved questions include how stable human mast-cell subtypes are, which experimental defense functions operate in natural human disease, and when mast cells promote rather than restrain chronic inflammation. Proposed roles in fibrosis and cancer are especially dependent on organ, disease stage, and interactions with other cells. Higher mast-cell density may correlate with an outcome without being its cause. Studies that distinguish cell number, activation state, mediator identity, and spatial relationships are necessary to resolve these different possibilities.